{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:14Z","timestamp":1792979894684,"version":"4.5.0"},"reference-count":22,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2025,3,26]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p> Refractory or resistant cytomegalovirus (CMV) infection and disease pose a significant challenge in immunocompromised patients, including solid organ transplant (SOT) and allogeneic hematopoietic cell transplant (allo-HCT) recipients. This study aimed to evaluate letermovir as a treatment for patients with CMV infection or disease. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> We performed an open-label, phase II non-randomized clinical trial. Adult and paediatric (\u226512 years of age) patients who had undergone an SOT or allo-HCT and who required antiviral treatment for refractory or resistant CMV or who had CMV with concurrent organ dysfunction were eligible. Patients received letermovir treatment daily for up to 12 weeks with an optional additional 12 weeks of therapy for secondary prophylaxis if clinically indicated. The primary objectives were to evaluate the safety and efficacy of letermovir treatment based upon virological and clinical responses. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Ten patients were enrolled in the study, and seven patients completed the study treatment and follow-up period. The overall virological response (defined as a complete virological response at the end of the study period) rate was 60% in the study population. The study drug was well tolerated, as only two patients experienced study drug-related toxicity and only one grade 3 toxicity (elevated ALT) was observed. Letermovir was not associated with acute kidney injury, hepatotoxicity, cardiac arrhythmias, or bone marrow suppression. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> In this limited sample, letermovir for CMV treatment was safe and well tolerated. Further research is needed to determine if letermovir can be used for the treatment of refractory or resistant CMV infection or disease. <\/jats:p><\/jats:sec>","DOI":"10.3138\/jammi-2024-0016","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T20:01:51Z","timestamp":1737403311000},"page":"6-14","source":"Crossref","is-referenced-by-count":3,"title":["Letermovir treatment for refractory or resistant cytomegalovirus infection or disease or with concurrent organ dysfunction: A phase 2 open label study"],"prefix":"10.3138","volume":"10","author":[{"given":"Matthew P","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Medical Microbiology, Department of Laboratory Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montreal, Quebec, Canada"},{"name":"Correspondence: Matthew P Cheng, MD, Division of Infectious Diseases, McGill University Health Centre, 1001 Decarie Boulevard, EM3.3218, Montreal, Quebec H4A 3J1 Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel H","family":"Gonzalez-Bocco","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA"},{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Arbonna-Haddad","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneerah","family":"Aleissa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Zhou","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Beluch","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Cho","sequence":"additional","affiliation":[{"name":"University of the Pacific, Arthur A. Dugoni School of Dentistry, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Burchett","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Moulton","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Texas Children's Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Desjardins","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases and Medical Microbiology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA"},{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA"},{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R","family":"Letourneau","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Divisions of Infectious Diseases and Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P","family":"Hammond","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Divisions of Infectious Diseases and Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas C","family":"Issa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA"},{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA"},{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"issue":"4","key":"r1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1574-6976.1999.tb00408.x","volume":"23","author":"Sweet C","year":"1999","journal-title":"FEMS Microbiol Rev"},{"issue":"11","key":"r2","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","volume":"50","author":"Bate SL","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"r3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","volume":"87","author":"Sinclair J","year":"2006","journal-title":"J Gen Virol"},{"issue":"11","key":"r4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","volume":"78","author":"Meesing A","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"r5","doi-asserted-by":"crossref","first-page":"e13080","DOI":"10.1111\/tid.13080","volume":"21","author":"Jorgenson MR","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"r6","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","volume":"23","author":"Yong MK","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"r7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","volume":"16","author":"Cantoni N","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"r8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12594","volume":"20","author":"Lumbreras C","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"16","key":"r9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","volume":"129","author":"Hill JA","year":"2017","journal-title":"Blood"},{"issue":"6","key":"r10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QCO.0000000000000409","volume":"30","author":"Haidar G","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"r11","unstructured":"Merck Canada Inc. Product Monograph Including Patient Information: PREVYMIS\u00ae letermovir tablets. 2020. https:\/\/pdf.hres.ca\/dpd_pm\/00056375.PDF"},{"issue":"1","key":"r12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","volume":"73","author":"Imlay HN","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"20","key":"r13","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","volume":"85","author":"Goldner T","year":"2011","journal-title":"J Virol"},{"issue":"25","key":"r14","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"Marty FM","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"r15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","volume":"330","author":"Limaye AP","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"r16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/ajt.15764","volume":"20","author":"Marty FM","year":"2020","journal-title":"Am J Transplant"},{"issue":"15","key":"r17","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","volume":"285","author":"Moher D","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"r18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"Ljungman P","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"r19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","volume":"68","author":"Papanicolaou GA","year":"2019","journal-title":"Clin Infect Dis"},{"key":"r20","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5","year":"2017"},{"issue":"10","key":"r21","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","volume":"59","author":"Chou S","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"r22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jcpt.13585","volume":"47","author":"Dickter JK","year":"2022","journal-title":"J Clin Pharm Ther"}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi-2024-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:22:49Z","timestamp":1746710569000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi-2024-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3,26]]}},"alternative-id":["10.3138\/jammi-2024-0016"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2024-0016","relation":{},"ISSN":["2371-0888"],"issn-type":[{"value":"2371-0888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}